No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

GEDSA Announces New Executive Director following Retirement of Previous Director

New Leadership in Non-Profit Focused on Patient Safety

Editor: What To Know

  • “I am happy that my departure from GEDSA comes at a time when we have reached such a large goal,” says Cusack, “our team has worked relentlessly to help increase awareness and education around the ISO 80369 standard to improve patient safety and I know it will not stop in my absence.
  • The transition to leadership appears to be a natural flow for the organization, pairing Davis' experience from the past with vision for the future holds much to look forward to from the non-profit.
  • Cusack has overseen GEDSA's patient safety initiatives around the globe, with a special attention this past year to reach ~50% conversion in the United States and ~45% conversion in Canada to the improved safety of the ENFit enteral feeding connectors.

On December 9, 2021, the Global Enteral Device Supplier Association (GEDSA), announced to its membership and supporting organizations, the Board of Directors’ official appointment of the new Executive Director, the latest update to the nonprofit’s leadership.

Following a long career of public service and industry leadership, (now former) GEDSA Executive Director, Michael K. Cusack announced his retirement from the nonprofit on December 3, 2021.

Cusack joined GEDSA in 2013 as a representative for GEDSA member, Xeridiem, then transitioned to Executive Director of GEDSA in 2018 with the goal of furthering patient safety around small bore connectors.

Cusack has overseen GEDSA’s patient safety initiatives around the globe, with a special attention this past year to reach ~50% conversion in the United States and ~45% conversion in Canada to the improved safety of the ENFit enteral feeding connectors.

“I am happy that my departure from GEDSA comes at a time when we have reached such a large goal,” says Cusack, “our team has worked relentlessly to help increase awareness and education around the ISO 80369 standard to improve patient safety and I know it will not stop in my absence.”

On December 8, 2021, GEDSA announced the election of its new Executive Director, Benjamin Davis. He is an Executive Engineer, previously of NeoMed, a part of the Avanos family of companies, who remains a GEDSA member today.

Davis has been involved in the ISO 80369 standard since 2012 and an active member since GEDSA was formalized in 2013. Recently he served as GEDSA’s Interim Chairman and acting Vice President of the Board of Directors. Davis has also served on multiple committees within GEDSA and has contributed to multiple studies that the organization has been involved with. He has also served as the member representative on GEDSA’s Clinical Advisory Board.

The transition to leadership appears to be a natural flow for the organization, pairing Davis’ experience from the past with vision for the future holds much to look forward to from the non-profit.

When asked about his new endeavor Davis replied, “GEDSA is an extraordinary organization in that it is comprised of medical device manufacturers who are all competitors, but they come together in the interest of patient safety. I’ve been proud to serve GEDSA through the years and I’m excited for this opportunity and for the future of the organization. GEDSA has played a crucial role in carrying out the ISO 80369 mission of patient safety and I’m honored to now lead and advance that mission.”

Amongst the changes, four Board of Directors seats come to term in January of 2022, as elected representatives of membership close out their three-year terms. GEDSA ran elections in November 2021 and elected the new representatives for the next three years, the new terms begin January 1, 2022.

GEDSA thanks its departing BOD members:

  • Franco Datillo, formerly of Boston Scientific
  • Ben Davis, formerly of NeoMed
  • Tom Hancock, Vesco
  • Patrick Delorme, Cair

GEDSA welcomes the newly elected BOD members:

  • Marc Waldman, Avanos
  • Paul van Raan, Nutricia
  • Kevin Maki, GBUK
  • Luis Pacheco, Smiths Medical

Those leaving their positions will remain active contributors within the organization under new leadership, in a different capacity. The changes within GEDSA spark excitement in the organization as it moves into its next chapter.

To learn more and see a full list of GEDSA members.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy